Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue: early-phase trial registry
A small indexed set (12 trials) with no open enrollment listed right now.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · none currently recruiting · #1,429 of 28,707 conditions by registered trial count
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue: 12 US clinical trials tracked, none currently recruiting.
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue is the subject of 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition extranodal-marginal-zone-b-cell-lymphoma-of-mucosa-associated-lymphoid-tissue
OPEN 0 | RECR 0% | LATE 0 | EARLY 12 | RANK #1429 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adenocarcinoma of the Gastroesophageal Junction (0% recruiting · 8 trials)
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue has no open enrollment in this registry pull (12 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue is recruiting below its size-band peers.
0 of 12 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue research.
Fred Hutchinson Cancer Center accounts for 3 of 12 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue trials plan to enrol fewer than 100 people.
Median target enrolment is 41 among the 12 trials that report a genuine target (sentinel values excluded). 10 of those (83.3%) plan for fewer than 100 participants.
-
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue research is mostly interventional.
12 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
12 total, page 1 of 1
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Kami Maddocks, MD
NCT01479842
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT01815749
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
NCT00918333
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
NCT00073918
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
Fred Hutchinson Cancer Center
NCT00867529
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
National Cancer Institute (NCI)
NCT01258998
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
NCT01261247
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
NCT00110071
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
University of Washington
NCT00601718
Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation
National Cancer Institute (NCI)
NCT00058305
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
Case Comprehensive Cancer Center
NCT01658319
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
NCT00769288
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue page
12 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Fred Hutchinson Cancer Center sponsors the most Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue condition card totals 12 registered trials; most-linked intervention laboratory biomarker analysis; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.